CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Venetoclax and HMA-based Therapies for the Treatment of Older and Unfit Adults with Newly Diagnosed FLT3-mutated AML: A myeloMATCH Treatment Trial
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
LUNA-2: LND101 in Unresectable Non-Small Cell Lung Cancer: A Randomized Phase II Trial
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
RAINBO-ORANGE: Treatment of Endometrial Cancer Based On Molecular Features
Delayed Reduced Volume and Dose Elective Ratiotherapy (REVERT) in Patients with HNSCC
CCTG presented Dr. Erica Tsang from Princess Margaret Cancer Centre the Dr. Elizabeth Eisenhauer Early Drug Development Young Investigator Award to recognize her work as a new investigator who has worked on IND projects and contributed significantly to the conduct of an IND trial at a member centre.
We are very honoured to present Jim Julian from McMaster University with the Excellence in Clinical Trials Conduct award which was graciously received by Jim at the CCTG Spring Meeting. The award is presented to an individual who exemplifies excellence in clinical trial operations and compliance.
"I would like to thank the CCTG and the DSMC Chair and Secretary for considering me for such an honour. I am happy to accept this recognition award.
The Phase III Team Award for CCTG-Led Trials was presented to the PR21 team from the BC Cancer at the Annual Spring Meeting this past weekend.
The MA40 trial, a double-blind placebo controlled randomized phase III trial of fulvestrant and ipatasertib as treatment for advanced HER-2 negative and estrogen receptor positive (ER+) breast cancer following progression on first line CDK 4/6 inhibitor and aromatase inhibitor has closed to further accrual as the accrual target of 250 study participants enrolled.
Please join the Patient Representative Committee in welcoming Michelle Audoin who will be supporting the Breast Disease Site committee.
